Prostate specific membrane antigen (PSMA) is a type of protein concentrated within the cells of a man’s prostate gland. It is substantially higher in malignant cells, which is why it is used as a “marker” for prostate cancer. PSMA PET/CT is a new type of PET/CT scan that measures prostate specific membrane antigen (PSMA).

PSMA PET/CT is approved for both initial staging of recently diagnosed prostate cancer, as well as the evaluation of possible local recurrence or metastatic disease in patients with previous treatment.

During a PET-CT scan, a special targeted tracer is injected into the body. The tracer binds to active PSMA molecules, enabling our radiologists to visualize the cancer cells. 

It is a superior technology for the staging of prostate cancer, with a 92% accuracy rate compared to 65% with conventional imaging. It is also used to help your doctor guide personalized treatment decisions. PSMA PET-CT provides such precise information, that in many cases it can help to increase the number and type of therapies available to treat prostate cancer.

For more information, please download our PSMA flyer here.
Skip to content